Fürst Daniel, Niederwieser Dietger, Bunjes Donald, Wagner Eva M, Gramatzki Martin, Wulf Gerald, Müller Carlheinz R, Neuchel Christine, Tsamadou Chrysanthi, Schrezenmeier Hubert, Mytilineos Joannis
Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg - Hessen, Ulm, Germany.
Institute of Transfusion Medicine, University of Ulm, Germany.
Haematologica. 2017 Apr;102(4):796-803. doi: 10.3324/haematol.2016.151340. Epub 2017 Jan 5.
We investigated a possible interaction between age-associated risk and HLA-mismatch associated risk on prognosis in different age categories of recipients of unrelated hematopoietic stem cell transplants (HSCT) (n=3019). Patients over 55 years of age transplanted with 8/10 donors showed a mortality risk of 2.27 (CI 1.70-3.03, <0.001) and 3.48 (CI 2.49-4.86, <0.001) when compared to 10/10 matched patients in the same age group and to 10/10 matched patients aged 18-35 years, respectively. Compared to 10/10 matched transplantations within each age category, the Hazards Ratio for 8/10 matched transplantation was 1.14, 1.40 and 2.27 in patients aged 18-35 years, 36-55 and above 55 years. Modeling age as continuous variable showed different levels of risk attributed to age at the time of transplantation [OS: 10/10: Hazards Ratio 1.015 (per life year); 9/10: Hazards Ratio: 1.019; 8/10: Hazards Ratio 1.026]. The interaction term was significant for 8/10 transplantations (=0.009). Findings for disease-free survival and transplant-related mortality were similar. Statistical models were stratified for diagnosis and included clinically relevant predictors except cytomegalovirus status and Karnofsky performance status. The risk conferred by age at the time of transplantation varies according to the number of HLA-mismatches and leads to a disproportional increase in risk for elderly patients, particularly with double mismatched donors. Our findings highlight the importance of HLA-matching, especially in patients over 55 years of age, as HLA-mismatches are less well tolerated in these patients. The interaction between age-associated risk and HLA-mismatches should be considered in donor selection and in the risk assessment of elderly HSCT recipients.
我们调查了非亲缘造血干细胞移植(HSCT)受者(n = 3019)不同年龄组中年龄相关风险与HLA错配相关风险对预后的可能相互作用。与同年龄组10/10配型患者及18 - 35岁10/10配型患者相比,55岁以上接受8/10供者移植的患者死亡风险分别为2.27(CI 1.70 - 3.03,<0.001)和3.48(CI 2.49 - 4.86,<0.001)。与各年龄组内10/10配型移植相比,18 - 35岁、36 - 55岁及55岁以上患者8/10配型移植的风险比分别为1.14、1.40和2.27。将年龄作为连续变量建模显示,移植时年龄导致的风险水平不同[总生存期:10/10:风险比1.015(每生命年);9/10:风险比:1.019;8/10:风险比1.026]。8/10移植的交互项显著(P = 0.009)。无病生存期和移植相关死亡率的结果相似。统计模型按诊断分层,纳入了除巨细胞病毒状态和卡诺夫斯基功能状态外的临床相关预测因素。移植时年龄带来的风险根据HLA错配数量而变化,导致老年患者风险不成比例增加,尤其是供者为双重错配时。我们的研究结果强调了HLA配型的重要性,特别是在55岁以上患者中,因为这些患者对HLA错配的耐受性较差。在供者选择和老年HSCT受者的风险评估中应考虑年龄相关风险与HLA错配之间的相互作用。